Equities researchers at HC Wainwright boosted their Q2 2025 earnings estimates for shares of BriaCell Therapeutics in a research report issued on Monday, February 3rd. HC Wainwright analyst E. Bodnar ...
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...
BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...
BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has ...
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...